Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 250Lymphoma 137Leukemia 124Burkitt Lymphoma 90Leukemia, Myeloid, Acute 69Lymphoma, Non-Hodgkin 65Lymphoma, Large B-Cell, Diffuse 59Myelodysplastic Syndromes 54Leukemia, Lymphocytic, Chronic, B-Cell 49Lymphoma, Mantle-Cell 47Hodgkin Disease 47Lymphoma, Follicular 45Leukemia, Myeloid, Accelerated Phase 39Multiple Myeloma 34Lymphoma, Large-Cell, Immunoblastic 33Leukemia, Myeloid, Chronic-Phase 33Recurrence 32Blast Crisis 32Lymphoma, B-Cell, Marginal Zone 31Congenital Abnormalities 31Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 30Myeloproliferative Disorders 30Leukemia, Biphenotypic, Acute 30Graft vs Host Disease 30Leukemia, Myelomonocytic, Chronic 28Dendritic Cell Sarcoma, Interdigitating 25Neoplasms, Plasma Cell 22Primary Myelofibrosis 21Lymphoma, T-Cell, Cutaneous 20Lymphoma, Large-Cell, Anaplastic 20

Interventions

Rituximab 4Doxorubicin 3Cyclophosphamide 3Vincristine 2Prednisone 2Etoposide 2pomalidomide 1merphos 1fludarabine 1brincidofovir 1Zidovudine 1Tomography, X-Ray Computed 1Polymerase Chain Reaction 1Nivolumab 1Methotrexate 1Leucovorin 1Interferons 1In Situ Hybridization 1Immunohistochemistry 1Hydroxyurea 1Flow Cytometry 1Echocardiography 1EPOCH protocol 1Cytogenetic Analysis 1Caves 1Brentuximab Vedotin 1Blotting, Western 1AP 1903 reagent 13-(4-chlorophenyl)-adamantane-1-carboxylic acid (pyridin-4-ylmethyl)amide 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Epstein-Barr Virus Infections × Methotrexate × Lymphoid × Clear all
NCT01964755 2019-09-23

Chemotherapy for Relapsed Epstein Barr Virus Associated Lymphoma

University of Miami

Phase 2 Terminated
6 enrolled 14 charts
Lymphoid

Hodgkin Disease, Lymphoma, Non-Hodgkin, Epstein-Barr Virus Infections

Data powered by HemOnc (CC BY 4.0) Colophon âš¡